Unichem Laboratories carries a decade-long shadow from an EU competition fine that was finally settled in FY2026, and its reported profits lean heavily on exceptional gains and accounting choices. The operating cash flow record is thin, a ring of loss-making foreign subsidiaries survives on parent support pledges, and the company fully impaired its ₹70.87 crore investment in the Brazil subsidiary. The auditor returned to unqualified opinions only after the fine was provided for, and a new ₹87 crore GST penalty demand is under appeal.
Key findings
- A decade-long EU competition fine was fully settled in FY2026 after losing final appeal
Major- The European Commission imposed a Euro 13.96 million fine on 9 July 2014 for an alleged competition-law breach, and the Court of Justice of the EU upheld it on 27 June 2024. Unichem made a full provision of ₹125.62 crore in FY2024 and settled the balance of Euro 16.76 million on 28 October 2025. A new CGST penalty demand of ₹87.07 crore was received on 24 January 2025 and remains under appeal. - Operating cash flow is chronically weak relative to reported profits
Major- Cumulative consolidated CFO over the ten years to FY26 was negative ₹653 crore against cumulative EBITDA of ₹347 crore, a ratio of -1.88x. The consolidated CFO/PAT ratio was 0.01x in FY26, and the company completed a buyback of 2.06 crore shares at ₹430 per share in FY18 while dividends were halted after FY22. - Audit opinions were qualified for two consecutive years due to the disputed EU fine
Major- The statutory auditor issued qualified opinions for FY2022 and FY2023 because the company did not impair its financial exposure in Niche Generics Limited related to the Euro 13.96 million fine. Opinions returned to unqualified from FY2024 onward after the fine was upheld and fully provided for. - Loss-making foreign subsidiaries survive on repeated parent support pledges
Major- Three subsidiaries, Niche Generics Ltd (UK), Unichem Farmaceutica Do Brasil Ltda, and Unichem China Pvt. Ltd., had accumulated losses in every year from FY20 through FY26 and were prepared on a going-concern basis only because the holding company pledged continuous financial support. The company fully impaired its ₹70.87 crore investment in the Brazil subsidiary and states it does not exercise significant influence over associate Synchron Research Services, whose carrying value is nil. - Promoter stake sold to Ipca Laboratories, and the board was reconstituted
Minor- Dr. Prakash A. Mody sold a 33.38% stake to Ipca Laboratories on 2 August 2023, reducing his holding from 46.16% to 12.78%, and Ipca's holding reached 52.67% by 21 September 2023. Mr. Pabitrakumar Bhattacharyya of Ipca was appointed Managing Director, and his FY2026 reappointment resolution includes a minimum remuneration clause payable under Schedule V in case of loss or inadequate profits. - The US subsidiary is the dominant intra-group conduit, with transaction limits at 117% of its standalone turnover
Minor- Shareholder approval was sought in February 2026 for related-party transactions with Unichem USA up to ₹1,600 crore for FY2027, against its FY2025 standalone turnover of ₹1,361.86 crore. The Board also approved a corporate guarantee of up to USD 50 million for Unichem USA's working capital facilities. - The statutory auditor has been in place since at least FY2020 with no reported resignations or regulatory actions
Clean- N. A. Shah Associates LLP has signed every audit report from FY2020 through FY2026 and was re-appointed for a second five-year term on 9 August 2022 with 98.03% votes in favour. The engagement partner rotated from Milan Mody to Bhavin Kapadia in FY2024.
What to watch
- MD reappointment vote. Shareholder vote on the reappointment of Mr. Pabitrakumar Bhattacharyya as MD for three years, with a minimum remuneration clause, at the 63rd AGM on 11 August 2026.
- CGST penalty appeal. Outcome of the appeal against the ₹87.07 crore penalty and ₹6.59 crore interest demand disclosed on 24 January 2025.
- UK Part 20 claim. Resolution of the Servier claim against Niche in the UK, where the contribution value was not yet quantified and defence had not been submitted as of 31 March 2025.
- Niche Generics exposure. Resolution of the unimpaired ₹59.28 crore exposure to Niche Generics that drew the FY2023 auditor qualification.
- Auditor rotation. Re-appointment or rotation of statutory auditors due at the 64th AGM in 2027.
Bottom line: This is a record where reported profit has been shaped by large exceptional items, accounting policy changes, and the non-recognition of deferred tax assets, while operating cash flow has run deeply negative over a decade. The EU fine saga is closed, but a new GST penalty demand is under appeal, and a ring of impaired, loss-making subsidiaries continues to rely on parent support. Watch the MD reappointment vote, the CGST appeal, and whether the Niche Generics exposure is finally resolved.